Investors focused on the Medical space have likely heard of Kamada , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Kamada is a member of our Medical group, which includes 833 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. KMDA is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for KMDA's full-year earnings has moved 33.33% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, KMDA has moved about 17.60% on a year-to-date basis. In comparison, Medical companies have returned an average of 10.44%. This means that Kamada is performing better than its sector in terms of year-to-date returns.
Breaking things down more, KMDA is a member of the Medical - Biomedical and Genetics industry, which includes 344 individual companies and currently sits at #89 in the Zacks Industry Rank. On average, this group has gained an average of 13.14% so far this year, meaning that KMDA is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on KMDA as it attempts to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of Kamada , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Kamada is a member of our Medical group, which includes 833 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. KMDA is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for KMDA's full-year earnings has moved 33.33% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, KMDA has moved about 17.60% on a year-to-date basis. In comparison, Medical companies have returned an average of 10.44%. This means that Kamada is performing better than its sector in terms of year-to-date returns.
Breaking things down more, KMDA is a member of the Medical - Biomedical and Genetics industry, which includes 344 individual companies and currently sits at #89 in the Zacks Industry Rank. On average, this group has gained an average of 13.14% so far this year, meaning that KMDA is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on KMDA as it attempts to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on KMDA - FREE